相关实验视频

Updated: Jul 7, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

通过基因调制解锁树突细胞基疫苗的有效性-现在有多快?

Ahmed Elwakeel¹, Hannah E Bridgewater¹, Jason Bennett²

¹Centre for Health and Life Sciences (CHLS), Coventry University, Coventry CV1 5FB, UK.

|December 23, 2023

概括

树突细胞 (DC) 疫苗旨在增强抗癌免疫力,但显示出令人失望的临床反应率. 正在探索基因工程策略,以提高DC疫苗的疗效,克服瘤免疫抑制.

科学领域:

免疫学免疫学免疫学
癌症治疗癌症治疗
细胞疗法细胞疗法

背景情况:

树突细胞 (DC) 疫苗是一种免疫治疗方法,使用充满瘤抗原的活体培养DC.
该策略旨在克服免疫抑制瘤微环境并增强抗瘤免疫反应.
尽管证实了安全性和可行性,但DC疫苗的临床反应率令人失望,限制了它们的全部潜力.

研究的目的:

审查基因工程战略,以优化树突细胞 (DC) 疫苗的疗效.
确定分子点,以提高DC疫苗在癌症免疫治疗中的性能.
评估DC疫苗在癌症免疫疗法更广泛的背景下的潜力.

主要方法:

关于DC疫苗策略的现有文献的审查.
评估基因工程方法来增强DC疫苗免疫性.
对DC生物学的分析,包括抗原吸收,成熟,迁移和T淋巴细胞初始化.

主要成果:

目前的DC疫苗策略面临着由于瘤微环境免疫抑制的挑战.
对于DC疫苗的临床响应率仍然低于最佳水平.
了解DC信号通路对于提高疫苗性能至关重要.

结论:

基因工程为提高DC疫苗疗效提供了潜在的途径.
需要对DC生物学和分子标进行进一步的研究,以优化DC疫苗.
在癌症免疫治疗中DC疫苗的最终作用尚未完全确定.

关键词:

基因编辑CRISPR基因编辑它们是RNAiRNAi.基于树突细胞的疫苗.树突细胞是一种树突细胞.基因工程是基因工程,是基因工程.

更多相关视频

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells

Published on: May 19, 2023

相关概念视频

Vaccinations

Vaccinations

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...